PNN DigitalPNN Digital
    Facebook Twitter Instagram
    Tuesday, June 24
    Trending
    • Midora Steam Oven’s Revolutionary Steam Technology by Hafele
    • Neetu Yoshi Limited IPO Opens on June 27, 2025
    • Shera Energy Deepens Global Integration with Zambian Copper Facility
    • Panchshil Bombay Sappers Soldierathon – A Tribute to the Heroes of Indian Armed Forces
    • Champions Choose The Best Tools: Golden Bullet’s Latest Film with Manu Bhaker Honors Skilled Professionals
    • EV Company, Supertech EV Plans To Raise Up To Rs. 29.90 Crore From Public Issue, IPO Opens On June 25, 2025
    • Cyberin Premium cPanel Hosting Is Smart Choice for Businesses in 2025
    • Zordo and Cyberin Announce Strategic Partnership to Deliver Digital Solutions
    Submit News
    PNN DigitalPNN Digital
    Subscribe
    • Home
    • News
    • Business
    • Entertainment
    • National
    • Lifestyle
    • More
      • Sports
      • Health
      • Finance
      • Education
    PNN DigitalPNN Digital
    Home»Health

    Eyestem files for IND approval for its product to treat geographic atrophy, the largest cause of incurable blindness in the world for people over 50

    PNN DigitalPNN Digital Health 2 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Bengaluru (Karnataka) [India], June 5: Dry age-related macular degeneration (dry AMD) is the largest cause of incurable blindness in the world for patients over 50 years. 170 million people suffer from this disease around the world, 25 million of which are in India. These numbers will, unfortunately, increase in the coming decades as our population ages. The more severe version of dry AMD is geographic atrophy, and no therapy is available to arrest or reverse this loss of vision.

    Eyestem Research today announced the submission of an Investigational New Drug (IND) application to the Central Drugs Standards Control Organization, India (CDSCO) to begin first-in-human trials of Eyecyte-RPE™for subjects with medium- and late-stage geographic atrophy, secondary to dry AMD.

    Dr. Rajani Battu, Chief Medical Officer of Eyestem Research, said, “We are excited to start human trials for Eyecyte-RPE™. Dry AMD is a huge disease burden, and this therapy has the potential to make a meaningful difference in our patient’s lives.”

    Dr. Jogin Desai, Chief Executive Officer of Eyestem Research, said, “Most cell and gene therapy products under development in the West are estimated to cost over US$ 200,000.Our vision is to democratize access to such treatments at a fraction of these costs and begin disruption of the current status quo with our Eyecyte-RPE™ product.”

    Eyestem Research is a deep science company incubated at the Centre for Cellular and Molecular Platforms, Bangalore, and supported by DBT-BIRAC as well as prestigious Indian and global healthcare investors. The IND submission for Eyecyte-RPE™is supported by robust GLP toxicology data from Dabur Research Foundation in India and excellent efficacy/safety data in animal models at Oregon Health and Science University. Validation of the injection technique and dose-finding studies were done in advanced animal models at the Singapore Eye Research Institute.

    About Eyecyte-RPE™

    Eyecyte-RPE™ is a patented suspension of iPSC-derived fate-committed retinal pigment epithelium cells, which are highly potent, safe, and efficacious in in-vitro and in-vivo studies. The cells are derived from induced pluripotent stem cells, are allogeneic in nature, and can be stored for long periods of time.

    If you have any objection to this press release content, kindly contact pr.error.rectification[at]gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.

    PNN Digital
    • Website

    Keep Reading

    Dr. Arpit Chopra Jain Honored at United Nations Headquarters in New York

    Indore to Host 7-Day Sickle Cell Awareness Campaign (June 13-20) Ahead of World Sickle Cell Day

    TrueFits App: India’s Fitness Game-Changer with AI Power

    TRANSFORM II Trial Hits Enrollment Milestone: Redefining Coronary Care with Sirolimus-Coated Balloons

    Introducing Hidoc Dr KOL Factory The Future Hub for Oncology Leaders Worldwide

    Apollo Hospitals Hyderabad Sets New Benchmark with AHA Comprehensive Chest Pain Centre Certification

    Recent Posts
    • Midora Steam Oven’s Revolutionary Steam Technology by Hafele
    • Neetu Yoshi Limited IPO Opens on June 27, 2025
    • Shera Energy Deepens Global Integration with Zambian Copper Facility
    • Panchshil Bombay Sappers Soldierathon – A Tribute to the Heroes of Indian Armed Forces
    • Champions Choose The Best Tools: Golden Bullet’s Latest Film with Manu Bhaker Honors Skilled Professionals

    Midora Steam Oven’s Revolutionary Steam Technology by Hafele

    23/06/2025

    Neetu Yoshi Limited IPO Opens on June 27, 2025

    23/06/2025

    Shera Energy Deepens Global Integration with Zambian Copper Facility

    23/06/2025

    Panchshil Bombay Sappers Soldierathon – A Tribute to the Heroes of Indian Armed Forces

    23/06/2025

    Champions Choose The Best Tools: Golden Bullet’s Latest Film with Manu Bhaker Honors Skilled Professionals

    23/06/2025

    EV Company, Supertech EV Plans To Raise Up To Rs. 29.90 Crore From Public Issue, IPO Opens On June 25, 2025

    23/06/2025
    Facebook Instagram Twitter
    • Legal Disclaimer
    • Privacy Policy
    • Contact Us
    • About Us
    © 2025 PNN Digital. Designed by Primex Media Services.

    Type above and press Enter to search. Press Esc to cancel.